How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
84
SHC Quote, Financials, Valuation and Earnings
Last price:
$18.12
Seasonality move
:
-9.68%
Day range:
$17.91 - $18.26
52-week range:
$9.53 - $19.85
Dividend yield:
0%
P/E ratio:
93.89x
P/S ratio:
4.50x
P/B ratio:
9.35x
Volume:
1.4M
Avg. volume:
1.8M
1-year change:
29.89%
Market cap:
$5.1B
Revenue:
$1.1B
EPS (TTM):
$0.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SHC
Sotera Health Co.
|
$300.7M | $0.24 | 6.09% | 463.53% | $20.44 |
|
FONR
FONAR Corp.
|
-- | -- | -- | -- | -- |
|
PRPH
ProPhase Labs, Inc.
|
$3.6M | -$0.15 | 3.99% | -50% | $13.80 |
|
TMO
Thermo Fisher Scientific, Inc.
|
$11.9B | $6.45 | 4.93% | 34.22% | $665.79 |
|
VCYT
Veracyte, Inc.
|
$135.8M | $0.41 | 14.08% | 263.61% | $47.67 |
|
XWEL
XWELL, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SHC
Sotera Health Co.
|
$18.12 | $20.44 | $5.1B | 93.89x | $0.00 | 0% | 4.50x |
|
FONR
FONAR Corp.
|
$18.64 | -- | $117.4M | 16.85x | $0.00 | 0% | 1.13x |
|
PRPH
ProPhase Labs, Inc.
|
$0.36 | $13.80 | $1.5M | -- | $0.00 | 0% | 0.25x |
|
TMO
Thermo Fisher Scientific, Inc.
|
$578.61 | $665.79 | $217.4B | 32.62x | $0.43 | 0.3% | 4.91x |
|
VCYT
Veracyte, Inc.
|
$38.08 | $47.67 | $3B | 100.32x | $0.00 | 0% | 6.12x |
|
XWEL
XWELL, Inc.
|
$0.32 | -- | $1.8M | -- | $0.00 | 0% | 0.06x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SHC
Sotera Health Co.
|
80.53% | 0.801 | 50.96% | 1.99x |
|
FONR
FONAR Corp.
|
18.59% | 1.184 | 49.09% | 9.64x |
|
PRPH
ProPhase Labs, Inc.
|
52.83% | 0.697 | 40.4% | 0.07x |
|
TMO
Thermo Fisher Scientific, Inc.
|
42.44% | 1.090 | 18.08% | 1.25x |
|
VCYT
Veracyte, Inc.
|
3.12% | 1.309 | 1.49% | 5.74x |
|
XWEL
XWELL, Inc.
|
278.04% | 2.325 | 65.46% | 0.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SHC
Sotera Health Co.
|
$174.5M | $125.4M | 1.98% | 11.79% | 40.29% | $33.4M |
|
FONR
FONAR Corp.
|
$10.4M | $3.2M | 4.68% | 5.84% | 12.26% | -$636K |
|
PRPH
ProPhase Labs, Inc.
|
-$650.5K | -$4.8M | -51.85% | -90.24% | -539.52% | -$3.5M |
|
TMO
Thermo Fisher Scientific, Inc.
|
$4.6B | $2.3B | 7.8% | 13.23% | 18.85% | $3B |
|
VCYT
Veracyte, Inc.
|
$89.4M | $23.1M | 2.43% | 2.52% | 17.53% | $42M |
|
XWEL
XWELL, Inc.
|
$1.3M | -$282K | -84.75% | -224.93% | -3.84% | -$3.1M |
Sotera Health Co. vs. Competitors
-
Which has Higher Returns SHC or FONR?
FONAR Corp. has a net margin of 15.55% compared to Sotera Health Co.'s net margin of 10.25%. Sotera Health Co.'s return on equity of 11.79% beat FONAR Corp.'s return on equity of 5.84%.
Company Gross Margin Earnings Per Share Invested Capital SHCSotera Health Co.56.04% $0.17 $2.8B FONRFONAR Corp.40.11% $0.34 $201.3M -
What do Analysts Say About SHC or FONR?
Sotera Health Co. has a consensus price target of $20.44, signalling upside risk potential of 12.79%. On the other hand FONAR Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sotera Health Co. has higher upside potential than FONAR Corp., analysts believe Sotera Health Co. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings SHCSotera Health Co.5 2 0 FONRFONAR Corp.0 0 0 -
Is SHC or FONR More Risky?
Sotera Health Co. has a beta of 1.822, which suggesting that the stock is 82.234% more volatile than S&P 500. In comparison FONAR Corp. has a beta of 0.993, suggesting its less volatile than the S&P 500 by 0.67700000000001%.
-
Which is a Better Dividend Stock SHC or FONR?
Sotera Health Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FONAR Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health Co. pays -- of its earnings as a dividend. FONAR Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SHC or FONR?
Sotera Health Co. quarterly revenues are $311.3M, which are larger than FONAR Corp. quarterly revenues of $26M. Sotera Health Co.'s net income of $48.4M is higher than FONAR Corp.'s net income of $2.7M. Notably, Sotera Health Co.'s price-to-earnings ratio is 93.89x while FONAR Corp.'s PE ratio is 16.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health Co. is 4.50x versus 1.13x for FONAR Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHCSotera Health Co.4.50x 93.89x $311.3M $48.4M FONRFONAR Corp.1.13x 16.85x $26M $2.7M
-
Which has Higher Returns SHC or PRPH?
ProPhase Labs, Inc. has a net margin of 15.55% compared to Sotera Health Co.'s net margin of -774.52%. Sotera Health Co.'s return on equity of 11.79% beat ProPhase Labs, Inc.'s return on equity of -90.24%.
Company Gross Margin Earnings Per Share Invested Capital SHCSotera Health Co.56.04% $0.17 $2.8B PRPHProPhase Labs, Inc.-73.67% -$1.65 $14.5M -
What do Analysts Say About SHC or PRPH?
Sotera Health Co. has a consensus price target of $20.44, signalling upside risk potential of 12.79%. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 37958.47%. Given that ProPhase Labs, Inc. has higher upside potential than Sotera Health Co., analysts believe ProPhase Labs, Inc. is more attractive than Sotera Health Co..
Company Buy Ratings Hold Ratings Sell Ratings SHCSotera Health Co.5 2 0 PRPHProPhase Labs, Inc.0 0 0 -
Is SHC or PRPH More Risky?
Sotera Health Co. has a beta of 1.822, which suggesting that the stock is 82.234% more volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.559, suggesting its less volatile than the S&P 500 by 155.946%.
-
Which is a Better Dividend Stock SHC or PRPH?
Sotera Health Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health Co. pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SHC or PRPH?
Sotera Health Co. quarterly revenues are $311.3M, which are larger than ProPhase Labs, Inc. quarterly revenues of $883K. Sotera Health Co.'s net income of $48.4M is higher than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, Sotera Health Co.'s price-to-earnings ratio is 93.89x while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health Co. is 4.50x versus 0.25x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHCSotera Health Co.4.50x 93.89x $311.3M $48.4M PRPHProPhase Labs, Inc.0.25x -- $883K -$6.8M
-
Which has Higher Returns SHC or TMO?
Thermo Fisher Scientific, Inc. has a net margin of 15.55% compared to Sotera Health Co.'s net margin of 16.21%. Sotera Health Co.'s return on equity of 11.79% beat Thermo Fisher Scientific, Inc.'s return on equity of 13.23%.
Company Gross Margin Earnings Per Share Invested Capital SHCSotera Health Co.56.04% $0.17 $2.8B TMOThermo Fisher Scientific, Inc.37.95% $5.21 $92.9B -
What do Analysts Say About SHC or TMO?
Sotera Health Co. has a consensus price target of $20.44, signalling upside risk potential of 12.79%. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $665.79 which suggests that it could grow by 14.64%. Given that Thermo Fisher Scientific, Inc. has higher upside potential than Sotera Health Co., analysts believe Thermo Fisher Scientific, Inc. is more attractive than Sotera Health Co..
Company Buy Ratings Hold Ratings Sell Ratings SHCSotera Health Co.5 2 0 TMOThermo Fisher Scientific, Inc.17 5 0 -
Is SHC or TMO More Risky?
Sotera Health Co. has a beta of 1.822, which suggesting that the stock is 82.234% more volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.907, suggesting its less volatile than the S&P 500 by 9.346%.
-
Which is a Better Dividend Stock SHC or TMO?
Sotera Health Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.3% to investors and pays a quarterly dividend of $0.43 per share. Sotera Health Co. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.7% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SHC or TMO?
Sotera Health Co. quarterly revenues are $311.3M, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $12.2B. Sotera Health Co.'s net income of $48.4M is lower than Thermo Fisher Scientific, Inc.'s net income of $2B. Notably, Sotera Health Co.'s price-to-earnings ratio is 93.89x while Thermo Fisher Scientific, Inc.'s PE ratio is 32.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health Co. is 4.50x versus 4.91x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHCSotera Health Co.4.50x 93.89x $311.3M $48.4M TMOThermo Fisher Scientific, Inc.4.91x 32.62x $12.2B $2B
-
Which has Higher Returns SHC or VCYT?
Veracyte, Inc. has a net margin of 15.55% compared to Sotera Health Co.'s net margin of 14.51%. Sotera Health Co.'s return on equity of 11.79% beat Veracyte, Inc.'s return on equity of 2.52%.
Company Gross Margin Earnings Per Share Invested Capital SHCSotera Health Co.56.04% $0.17 $2.8B VCYTVeracyte, Inc.67.76% $0.24 $1.3B -
What do Analysts Say About SHC or VCYT?
Sotera Health Co. has a consensus price target of $20.44, signalling upside risk potential of 12.79%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.67 which suggests that it could grow by 25.18%. Given that Veracyte, Inc. has higher upside potential than Sotera Health Co., analysts believe Veracyte, Inc. is more attractive than Sotera Health Co..
Company Buy Ratings Hold Ratings Sell Ratings SHCSotera Health Co.5 2 0 VCYTVeracyte, Inc.8 2 1 -
Is SHC or VCYT More Risky?
Sotera Health Co. has a beta of 1.822, which suggesting that the stock is 82.234% more volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.876, suggesting its more volatile than the S&P 500 by 87.569%.
-
Which is a Better Dividend Stock SHC or VCYT?
Sotera Health Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health Co. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SHC or VCYT?
Sotera Health Co. quarterly revenues are $311.3M, which are larger than Veracyte, Inc. quarterly revenues of $131.9M. Sotera Health Co.'s net income of $48.4M is higher than Veracyte, Inc.'s net income of $19.1M. Notably, Sotera Health Co.'s price-to-earnings ratio is 93.89x while Veracyte, Inc.'s PE ratio is 100.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health Co. is 4.50x versus 6.12x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHCSotera Health Co.4.50x 93.89x $311.3M $48.4M VCYTVeracyte, Inc.6.12x 100.32x $131.9M $19.1M
-
Which has Higher Returns SHC or XWEL?
XWELL, Inc. has a net margin of 15.55% compared to Sotera Health Co.'s net margin of -2.87%. Sotera Health Co.'s return on equity of 11.79% beat XWELL, Inc.'s return on equity of -224.93%.
Company Gross Margin Earnings Per Share Invested Capital SHCSotera Health Co.56.04% $0.17 $2.8B XWELXWELL, Inc.17.32% -$0.26 $13M -
What do Analysts Say About SHC or XWEL?
Sotera Health Co. has a consensus price target of $20.44, signalling upside risk potential of 12.79%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 2118.7%. Given that XWELL, Inc. has higher upside potential than Sotera Health Co., analysts believe XWELL, Inc. is more attractive than Sotera Health Co..
Company Buy Ratings Hold Ratings Sell Ratings SHCSotera Health Co.5 2 0 XWELXWELL, Inc.0 0 0 -
Is SHC or XWEL More Risky?
Sotera Health Co. has a beta of 1.822, which suggesting that the stock is 82.234% more volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.326, suggesting its more volatile than the S&P 500 by 32.585%.
-
Which is a Better Dividend Stock SHC or XWEL?
Sotera Health Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sotera Health Co. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SHC or XWEL?
Sotera Health Co. quarterly revenues are $311.3M, which are larger than XWELL, Inc. quarterly revenues of $7.3M. Sotera Health Co.'s net income of $48.4M is higher than XWELL, Inc.'s net income of -$211K. Notably, Sotera Health Co.'s price-to-earnings ratio is 93.89x while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sotera Health Co. is 4.50x versus 0.06x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SHCSotera Health Co.4.50x 93.89x $311.3M $48.4M XWELXWELL, Inc.0.06x -- $7.3M -$211K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
